C L Arteaga

Summary

Affiliation: Vanderbilt University
Country: USA

Publications

  1. ncbi Epidermal growth factor receptor dependence in human tumors: more than just expression?
    Carlos L Arteaga
    Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6307, USA
    Oncologist 7:31-9. 2002
  2. ncbi Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site
    C L Arteaga
    Department of Medicine, Vanderbilt University School of Medicine, Vanderbilt Cancer Center, Nashville, Tennessee 37232 5536, USA
    J Biol Chem 272:23247-54. 1997
  3. ncbi Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta
    C L Arteaga
    Department of Medicine, Vanderbilt University School of Medicine, Vanderbilt Cancer Center, Department of Veterans Affairs Medical Center, Nashville, TN 37232 5536, USA
    J Natl Cancer Inst 91:46-53. 1999
  4. ncbi The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia
    C L Arteaga
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    J Clin Oncol 19:32S-40S. 2001
  5. ncbi Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice
    A E Lenferink
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Proc Natl Acad Sci U S A 97:9609-14. 2000
  6. ncbi ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways
    A E Lenferink
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Cancer Res 61:6583-91. 2001
  7. ncbi Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo
    S L Moulder
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6307, USA
    Cancer Res 61:8887-95. 2001
  8. ncbi Transforming growth factor beta enhances epithelial cell survival via Akt-dependent regulation of FKHRL1
    I Shin
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Mol Biol Cell 12:3328-39. 2001
  9. ncbi Tyrosine kinase inhibitors: rationale, mechanisms of action, and implications for drug resistance
    D Busse
    Departments of Medicine and Cell Biology, Vanderbilt University School of Medicine, Nashville, TN, USA
    Semin Oncol 28:47-55. 2001
  10. ncbi Inhibitors of HER2/neu (erbB-2) signal transduction
    C L Arteaga
    Department of Medicine, Vanderbilt University School of Medicine, 22nd Avenue S, 1956 TVC, Nashville, TN 37232-5536, USA
    Semin Oncol 28:30-5. 2001

Collaborators

Detail Information

Publications80

  1. ncbi Epidermal growth factor receptor dependence in human tumors: more than just expression?
    Carlos L Arteaga
    Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6307, USA
    Oncologist 7:31-9. 2002
    ....
  2. ncbi Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site
    C L Arteaga
    Department of Medicine, Vanderbilt University School of Medicine, Vanderbilt Cancer Center, Nashville, Tennessee 37232 5536, USA
    J Biol Chem 272:23247-54. 1997
    ....
  3. ncbi Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta
    C L Arteaga
    Department of Medicine, Vanderbilt University School of Medicine, Vanderbilt Cancer Center, Department of Veterans Affairs Medical Center, Nashville, TN 37232 5536, USA
    J Natl Cancer Inst 91:46-53. 1999
    ..We investigated whether inhibition of TGF-beta2, which is overexpressed in LCC2 tamoxifen-resistant human breast cancer cells, could modify antiestrogen resistance...
  4. ncbi The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia
    C L Arteaga
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    J Clin Oncol 19:32S-40S. 2001
    ....
  5. ncbi Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice
    A E Lenferink
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Proc Natl Acad Sci U S A 97:9609-14. 2000
    ..These data suggest that increased signaling by ErbB receptors up-regulates MAPK activity, which, in turn, phosphorylates and destabilizes p27, thus contributing to dysregulated cell cycle progression...
  6. ncbi ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways
    A E Lenferink
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Cancer Res 61:6583-91. 2001
    ....
  7. ncbi Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo
    S L Moulder
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6307, USA
    Cancer Res 61:8887-95. 2001
    ....
  8. ncbi Transforming growth factor beta enhances epithelial cell survival via Akt-dependent regulation of FKHRL1
    I Shin
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Mol Biol Cell 12:3328-39. 2001
    ..Finally, dominant-negative Akt abrogated the antiapoptotic effect of TGF beta. Taken together, these data suggest that TGF beta may play a role in epithelial cell survival via Akt-dependent regulation of FKHRL1...
  9. ncbi Tyrosine kinase inhibitors: rationale, mechanisms of action, and implications for drug resistance
    D Busse
    Departments of Medicine and Cell Biology, Vanderbilt University School of Medicine, Nashville, TN, USA
    Semin Oncol 28:47-55. 2001
    ..Many of these small molecules are in different stages of preclinical and clinical development against several solid tumors and will be discussed...
  10. ncbi Inhibitors of HER2/neu (erbB-2) signal transduction
    C L Arteaga
    Department of Medicine, Vanderbilt University School of Medicine, 22nd Avenue S, 1956 TVC, Nashville, TN 37232-5536, USA
    Semin Oncol 28:30-5. 2001
    ..This report will focus on one of these anti-HER2 signaling strategies...
  11. ncbi Tyrosine kinase inhibitors-ZD1839 (Iressa)
    C L Arteaga
    Breast Cancer Program Vanderbilt-Ingram Cancer, Vanderbilt University School of Medicine, 777 Preston Research Building, Nashville, Tennessee 37232-6307, USA
    Curr Opin Oncol 13:491-8. 2001
    ..The early results of clinical trials indicate this drug possesses antitumor activity in certain malignancies of the upper aerodigestive tract...
  12. ncbi Mechanisms of resistance development against trastuzumab (Herceptin) in an in vivo breast cancer model
    C A Ritter
    Department of Hematology-Oncology and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA
    Int J Clin Pharmacol Ther 42:642-3. 2004
  13. ncbi Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer
    H Kurokawa
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Clin Cancer Res 7:4436s-4442s; discussion 4411s-4412s. 2001
    ....
  14. ncbi H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3
    A Chakrabarty
    Department of Medicine, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA
    Oncogene 29:5193-203. 2010
    ..These data also suggest that mammary tumors that contain both HER2 gene amplification and PIK3CA mutations should be treated with a combination of HER2 and PI3K inhibitors...
  15. ncbi Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression
    R S Muraoka-Cook
    Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Oncogene 25:3408-23. 2006
    ....
  16. ncbi Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition
    B N Rexer
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
    Oncogene 30:4163-74. 2011
    ....
  17. ncbi Growth retardation and tumour inhibition by BRCA1
    J T Holt
    Department of Cell Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 2175, USA
    Nat Genet 12:298-302. 1996
    ..Most importantly, among mice with established MCF-7 tumours, peritoneal treatment with a retroviral vector expressing wild-type BRCA1 significantly inhibits tumour growth and increased survival...
  18. ncbi Cyclin-dependent kinase inhibitor p27(Kip1) is required for mouse mammary gland morphogenesis and function
    R S Muraoka
    Department of Cell Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    J Cell Biol 153:917-32. 2001
    ..Therefore, p27 is required for mammary gland development in a dose-dependent fashion and positively regulates cyclin D-Cdk4 function in the mammary gland...
  19. ncbi Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas
    C L Arteaga
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232
    Proc Natl Acad Sci U S A 88:10435-9. 1991
    ....
  20. ncbi Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations
    Marianela Perez-Torres
    Department of Cancer Biology, Vanderbilt-Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    J Biol Chem 281:40183-92. 2006
    ..These data suggest that cetuximab is an effective therapy against mutant EGFR-expressing cancer cells and thus can be considered in combination with other anti-EGFR molecules...
  21. ncbi HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor beta
    Shizhen Emily Wang
    Department of Cancer Biology, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Cancer Res 66:9591-600. 2006
    ..Thus, by recruiting the actin skeleton, TGF-beta "cross-links" this signaling complex at cell lamellipodia; this prolongs Rac1 activation and increases metastatic properties and survival of HER2-overexpressing cells...
  22. ncbi Gene targeting of ErbB3 using a Cre-mediated unidirectional DNA inversion strategy
    Shimian Qu
    Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6838, USA
    Genesis 44:477-86. 2006
    ..Unidirectional DNA inversion by in vivo recombination is an effective strategy for targeted or ubiquitous gene knockout...
  23. ncbi Inhibition of transforming growth factor-beta signaling in human cancer: targeting a tumor suppressor network as a therapeutic strategy
    Swati Biswas
    Department of Medicine, Breast Cancer Research Program, Vanderbilt-Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6307, USA
    Clin Cancer Res 12:4142-6. 2006
  24. ncbi Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors
    Seungchan Yang
    Department of Medicine, Breast Cancer Research Program, Vanderbilt-Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6307, USA
    Cancer Res 66:6990-7. 2006
    ..These results suggest that EGFR mutants form defective endocytic complexes. In addition, HSP90 plays a role in maintaining the functional conformation of EGFR mutants and protecting activated receptors from LIRD...
  25. ncbi Knockdown of the transforming growth factor-beta type III receptor impairs motility and invasion of metastatic cancer cells
    Tracy L Criswell
    Department of Cancer Biology, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Cancer Res 68:7304-12. 2008
    ..These data indicate that TbetaRIII differentially regulates cell growth, motility, and invasion in tumorigenic MDA-231 and PMTLuc cells and that these growth changes occur through the modulation of NF-kappaB activity...
  26. ncbi Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors?
    Carlos L Arteaga
    J Clin Oncol 24:3722-5. 2006
  27. ncbi Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers
    Marta Guix
    Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    J Clin Oncol 26:897-906. 2008
    ....
  28. ncbi EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans
    Carlos L Arteaga
    Department of Medicine, Breast Cancer Research Program, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Cancer Cell 9:421-3. 2006
    ..These mouse models provide important opportunities for studying the biology of NSCLC and the refinement of anti-EGFR therapies...
  29. ncbi Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity
    Frederick Y Wu
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Cancer Res 66:2162-72. 2006
    ..These data suggest that cytoplasmic p27 can exert oncogenic functions by modulating Akt stability, cell survival, and tumorigenicity...
  30. ncbi ErbB receptor signaling and therapeutic resistance to aromatase inhibitors
    Incheol Shin
    Department of Cancer Biology, Vanderbilt-Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, University Medical Center, 2220 Pierce Avenue, Nashville, TN 37232, USA
    Clin Cancer Res 12:1008s-1012s. 2006
    ..These results suggest that ligand-independent recruitment of coactivator complexes to estrogen-responsive promoters as a result of HER-2 overexpression may play a role in the development of letrozole resistance...
  31. ncbi Inhibition of TGFbeta signaling in cancer therapy
    Carlos L Arteaga
    Department of Medicine, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA
    Curr Opin Genet Dev 16:30-7. 2006
    ..This suggests opportunities for dissecting molecular mechanisms of cross-talk as well as providing insights into possible combinatorial molecular anticancer therapies that will include TGFbeta inhibitors...
  32. ncbi Convergence of p53 and transforming growth factor beta (TGFbeta) signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells
    Shizhen Emily Wang
    Department of Cancer Biology, Mass Spectrometry Research Center, Breast Cancer Research Program, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    J Biol Chem 282:5661-9. 2007
    ..Taken together, these data support cooperation between the p53 and TGFbeta tumor suppressor pathways in the induction of Maspin expression, thus leading to inhibition of cell migration...
  33. ncbi Will single-time tumor profiling and a "guilt by association" approach allow us to outsmart HER2-positive breast cancer?
    Carlos L Arteaga
    Clin Cancer Res 13:1071-3. 2007
  34. ncbi relocating job wise? A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor
    Peter Hinow
    Department of Mathematics, Vanderbilt University, Nashville, TN 37240, USA
    Theor Biol Med Model 4:14. 2007
    ..A mathematical model was used to interpret the experimental data...
  35. ncbi Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab
    Shizhen Emily Wang
    Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Mol Cell Biol 28:5605-20. 2008
    ....
  36. ncbi Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells
    Abbes Belkhiri
    Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Clin Cancer Res 14:4564-71. 2008
    ..We have investigated the role of t-DARPP in trastuzumab resistance in ERBB2-amplified and overexpressed breast cancer cell lines...
  37. ncbi Multivariable difference gel electrophoresis and mass spectrometry: a case study on transforming growth factor-beta and ERBB2 signaling
    David B Friedman
    Mass Spectrometry Research Center, Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Mol Cell Proteomics 6:150-69. 2007
    ..Several proteins with a potential role in breast cancer, such as maspin and cathepsin D, were identified as novel molecules associated with TGF-beta signaling...
  38. ncbi Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins
    Marta Guix
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6307, USA
    J Clin Invest 118:2609-19. 2008
    ..Moreover, combined therapeutic inhibition of EGFR and IGFIR may abrogate this acquired mechanism of drug resistance and is thus worthy of prospective clinical investigation...
  39. ncbi Differentiating proteomic biomarkers in breast cancer by laser capture microdissection and MALDI MS
    Melinda E Sanders
    Department of Pathology, Vanderbilt University, Nashville, Tennessee 37232, USA
    J Proteome Res 7:1500-7. 2008
    ..Several of the m/ z features used in the classifiers were identified by LC-MS/MS and two were confirmed by immunohistochemistry...
  40. ncbi Does gefitinib shorten lung cancer survival? Chaos redux
    Vicki L Keedy
    J Clin Oncol 26:2428-30. 2008
  41. ncbi Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel
    Ayana Sawai
    Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Res 68:589-96. 2008
    ....
  42. ncbi Modulation of NFkappaB activity and E-cadherin by the type III transforming growth factor beta receptor regulates cell growth and motility
    Tracy L Criswell
    Department of Cancer Biology, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    J Biol Chem 282:32491-500. 2007
    ..These data indicate that TbetaRIII acts as a tumor suppressor in nontumorigenic mammary epithelial cells at least in part by inhibiting NFkappaB-mediated repression of E-cadherin...
  43. ncbi Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network
    Christoph A Ritter
    Institute of Pharmacology, University of Greifswald, Greifswald, Germany
    Clin Cancer Res 13:4909-19. 2007
    ..We have investigated mechanisms of acquired resistance to the HER2 antibody trastuzumab in BT-474 human breast cancer cells...
  44. ncbi Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer
    Li Yang
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Cancer Res 67:5587-93. 2007
    ..This effect is reversible in a subset of NSCLC upon treatment with an EGFR TKI...
  45. ncbi HER3 and mutant EGFR meet MET
    Carlos L Arteaga
    Nat Med 13:675-7. 2007
  46. ncbi Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells
    Alyssa R Bonine Summers
    Department of Cancer Biology, Vanderbilt lngram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee 37232 6838, USA
    Cancer Biol Ther 6:561-70. 2007
    ..These results provide a novel mechanism of action for EGFR as a mediator of HGF signaling thereby linking EGFR to the oncogenic potential of c-Met in mammary carcinomas cells...
  47. ncbi Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression
    Swati Biswas
    Department of Cancer Biology, Breast Cancer Research Program, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, 2220 Pierce Avenue, Nashville, TN 37232, USA
    J Clin Invest 117:1305-13. 2007
    ..These data implicate TGF-beta induced by anticancer therapy as a pro-metastatic signal in tumor cells and provide a rationale for the simultaneous use of these therapies in combination with TGF-beta inhibitors...
  48. ncbi HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors
    Shizhen Emily Wang
    Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Cancer Cell 10:25-38. 2006
    ..These data suggest that (1) HER2(YVMA) activates cellular substrates more potently than HER2(WT); and (2) cancer cells expressing this mutation remain sensitive to HER2-targeted therapies but insensitive to EGFR TKIs...
  49. ncbi Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function
    Shizhen Emily Wang
    Division of Oncology, Department of Cancer Biology, Vanderbilt University School of Medicine, 2220 Pierce Ave, 777 PRB, Nashville, TN 37232 6307, USA
    Mol Cell Biol 25:4703-15. 2005
    ....
  50. ncbi Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors
    Roberto Bianco
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
    Oncogene 22:2812-22. 2003
    ..Thus, in EGFR-expressing tumor cells with concomitant amplification(s) of PI3K-Akt signaling, combined blockade of the EGFR tyrosine kinase and Akt should be considered as a therapeutic approach...
  51. ncbi Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice
    Carlos L Arteaga
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6307, USA
    Clin Cancer Res 9:1579-89. 2003
  52. ncbi Molecular therapeutics: is one promiscuous drug against multiple targets better than combinations of molecule-specific drugs?
    Carlos L Arteaga
    Clin Cancer Res 9:1231-2. 2003
  53. ncbi ErbB-targeted therapeutic approaches in human cancer
    Carlos L Arteaga
    Department of Medicine, Vanderbilt University School of Medicine, and Breast Cancer Program, Vanderbilt Ingram Comprehensive Cancer Center, Nashville, TN 37232, USA
    Exp Cell Res 284:122-30. 2003
    ....
  54. ncbi The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors
    Christoph A Ritter
    Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232-6307, USA
    Semin Oncol 30:3-11. 2003
    ..ZD1839 (Iressa; AstraZeneca Pharmaceuticals LP, Wilmington, DE) is the EGFR-TK inhibitor furthest along in clinical development, and it is currently being investigated in a variety of solid tumors, including non-small-cell lung cancer...
  55. ncbi Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer
    Carlos L Arteaga
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Breast Cancer Res 5:96-100. 2003
    ....
  56. ncbi Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia
    Carlos L Arteaga
    Departments of Medicine and Cancer Biology and the Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232-6307, USA
    Semin Oncol 29:3-9. 2002
    ..Early clinical studies already suggest that both of these approaches, either alone or in combination with standard anticancer therapies, alter the natural history of EGFR-expressing cancers with little toxicity to the tumor-bearing host...
  57. ncbi Autocrine transforming growth factor-beta signaling mediates Smad-independent motility in human cancer cells
    Nancy Dumont
    Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    J Biol Chem 278:3275-85. 2003
    ....
  58. ncbi PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization
    Incheol Shin
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Nat Med 8:1145-52. 2002
    ..These data indicate that Akt may contribute to tumor-cell proliferation by phosphorylation and cytosolic retention of p27, thus relieving CDK2 from p27-induced inhibition...
  59. ncbi TGFbeta1 -mediated epithelial to mesenchymal transition is accompanied by invasion in the SiHa cell line
    Jae Youn Yi
    Laboratory of Tissue Engineering, Korea Cancer Center Hospital, Seoul
    Eur J Cell Biol 81:457-68. 2002
    ..In conclusion, TGFbeta1 stimulated epithelial-mesenchymal transition of SiHa cells, indicating a positive role in the invasive transition of tumors...
  60. ncbi HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer
    Carlos L Arteaga
    Departments of Medicine and Cancer Biology and the Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232-6307, USA
    Semin Oncol 29:4-10. 2002
    ..A rational therapeutic approach that builds on these results with trastuzumab and expands the targeting of the HER network will be presented...
  61. ncbi Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action
    F Michael Yakes
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Cancer Res 62:4132-41. 2002
    ....
  62. ncbi Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases
    Rebecca S Muraoka
    Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 27232, USA
    J Clin Invest 109:1551-9. 2002
    ..Therefore, blockade of TGF-beta signaling may reduce tumor cell viability and migratory potential and represents a testable therapeutic approach against metastatic carcinomas...
  63. ncbi Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer
    Carlos L Arteaga
    Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232-6307, USA
    Semin Oncol 29:15-26. 2002
    ..We will review some of the more recent treatment strategies in non-small cell and small cell lung cancer targeted to dysregulated signaling pathways that are causally associated with tumor maintenance and progression...
  64. ncbi Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?
    David H Johnson
    J Clin Oncol 21:2227-9. 2003
  65. ncbi Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells
    Keith E Matheny
    Vanderbilt Bill Wilkerson Department of Otolaryngology Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Laryngoscope 113:936-9. 2003
    ..Downregulation of p63 by ZD1839 would identify a potential molecular relationship between EGFR signaling and p63 and could provide insight into the mechanism of action of ZD1839...
  66. ncbi Critical update and emerging trends in epidermal growth factor receptor targeting in cancer
    Jose Baselga
    Medical Oncology Service, Vall d Hebron Research Institute and Vall d Hebron University Hospital, Paseo Vall d Hebron 119 129, Barcelona 08035, Spain
    J Clin Oncol 23:2445-59. 2005
    ....
  67. ncbi Type I transforming growth factor beta receptor binds to and activates phosphatidylinositol 3-kinase
    Jae Youn Yi
    Department of Medicine and Cancer Biology, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    J Biol Chem 280:10870-6. 2005
    ....
  68. ncbi Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics
    Michelle L Reyzer
    Mass Spectrometry Research Center, Department of Biochemistry, Vanderbilt-Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Cancer Res 64:9093-100. 2004
    ..These results suggest that drug-induced early proteomic changes as measured by MALDI-MS can be used to predict the therapeutic response to established and novel therapies...
  69. ncbi Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors
    Rebecca S Muraoka-Cook
    Department of Cancer Biology, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Cancer Res 64:9002-11. 2004
    ..Therefore, induction and/or activation of TGF-beta in hosts with established TGF-beta-responsive cancers can rapidly accelerate metastatic progression...
  70. ncbi Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?
    Carlos L Arteaga
    Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Cancer Cell 5:525-31. 2004
    ....
  71. ncbi Selecting the right patient for tumor therapy
    Carlos L Arteaga
    Nat Med 10:577-8. 2004
  72. ncbi Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancer
    Carlos L Arteaga
    Department of Medicine, Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA
    Semin Oncol 31:3-8. 2004
    ..A point of view regarding challenges in the development of anti-EGFR therapies for patients with breast cancer and possible approaches to overcome them is presented in this article...
  73. ncbi Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility
    Yukiko Ueda
    Department of Medicine, Vanderbilt University School of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Nashville, Tennessee 37232, USA
    J Biol Chem 279:24505-13. 2004
    ....
  74. ncbi Modeling the cancer patient with genetically engineered mice: prediction of toxicity from molecule-targeted therapies
    Reade B Roberts
    Department of Genetics, University of North Carolina, Chapel Hill, NC 27599, USA
    Cancer Cell 5:115-20. 2004
    ..Here we review and propose how genetically engineered mouse models can serve as valuable tools to predict targeted therapy toxicity, as well as to identify allelic variants that predispose individuals to side effects...
  75. ncbi Transforming growth factor-beta induces Cdk2 relocalization to the cytoplasm coincident with dephosphorylation of retinoblastoma tumor suppressor protein
    Kimberly A Brown
    Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA
    Breast Cancer Res 6:R130-9. 2004
    ....
  76. ncbi Cdk inhibitor p27Kip1 and hormone dependence in breast cancer
    Carlos L Arteaga
    Departments of Medicine and Cancer Biology and Breast Cancer Program, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Clin Cancer Res 10:368S-71S. 2004
    ..These results imply that hormone receptor-positive tumors with low and/or cytosolic p27 respond poorly to antiestrogens and should be considered for alternative therapeutic strategies...
  77. ncbi EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs
    Carlos L Arteaga
    Department of Medicine and Cancer Biology and Breat Cancer Program, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    J Clin Oncol 21:289s-291s. 2003
    ..This approach would also exclude patients for whom these drugs will not induce any clinical benefit...
  78. ncbi Inhibiting tyrosine kinases: successes and limitations
    Carlos L Arteaga
    Department of Medicine, Vanderbilt Ingram Cancer Center, Varderbilt University School of Medicine, Nashville, TN 37232 6307, US
    Cancer Biol Ther 2:S79-83. 2003
    ....
  79. ncbi A Phase I/II Trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2)
    Stacy L Moulder
    Comprehensive Breast Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Clin Breast Cancer 4:142-5. 2003
  80. ncbi ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells
    Rebecca S Muraoka
    Department of Cancer Biology, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Mol Cell Biol 22:2204-19. 2002
    ..These results suggest that p27(+/-) mammary epithelium may be more susceptible to oncogene-induced tumorigenesis, whereas p27-null glands, due to severely impaired cyclin D1/Cdk4 function, are more resistant to transformation...